Lucie Y. Li

Berlin, BE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Journal: Research square
Published: March 27, 2026

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells.

Journal: Research square
Published: March 27, 2026

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.

Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models.

Journal: Nature communications
Published: March 11, 2026

Binding of established antinuclear antibodies to neurons depends on tissue fixation and underlying autoantigens.

Binding of established antinuclear antibodies to neurons depends on tissue fixation and underlying autoantigens.

Journal: Frontiers in immunology
Published: July 28, 2025

Antibodies in neurological diseases: Established, emerging, explorative.

Antibodies in neurological diseases: Established, emerging, explorative.

Journal: Immunological reviews
Published: October 01, 2024

Brain-targeting autoantibodies in patients with dementia.

Brain-targeting autoantibodies in patients with dementia.

Journal: Frontiers in neurology
Published: April 05, 2024

IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS).

IA-PACS-CFS: a double-blinded, randomized, sham-controlled, exploratory trial of immunoadsorption in patients with chronic fatigue syndrome (CFS) including patients with post-acute COVID-19 CFS (PACS-CFS).

Journal: Trials
Published: September 11, 2023

Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.

Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells.

Journal: Cell
Published: April 19, 2023

Immunoreactivity to astrocytes in different forms of dementia: High prevalence of autoantibodies to GFAP.

Immunoreactivity to astrocytes in different forms of dementia: High prevalence of autoantibodies to GFAP.

Journal: Brain, behavior, & immunity - health
Published: October 25, 2022

Brain blood vessel autoantibodies in patients with NMDA and GABAA receptor encephalitis: identification of unconventional Myosin-X as target antigen.

Brain blood vessel autoantibodies in patients with NMDA and GABAA receptor encephalitis: identification of unconventional Myosin-X as target antigen.

Journal: Frontiers in cellular neuroscience
Published: October 22, 2022

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.

A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model.

Journal: bioRxiv : the preprint server for biology
Published: August 21, 2020

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.

A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model.

Journal: Cell
Published: August 11, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026